null

null

null

null

null

null

null

null

null

0.06x Total Debt / Equity (Conservative)

Low-moderate; EW carries ~$600M net debt, investment-grade rated; 200bps rate rise increases annual interest expense ~$12M, <1% of revenue impact

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Taiwan/East Asia semiconductor fabrication for sensor components; single-source nitinol suppliers concentrated in U.S./Japan with limited alternative sourcing

EUR (~25% of international revenue), JPY (~10%), CNY (~8%) exposure; JPY depreciation 15% YoY created ~$50M headwind; EUR weakness adds ~$30M annual FX drag

Top markets: Europe (EUR), Japan (JPY), China (CNY); combined ~40% of total revenue; JPY and CNY devaluation risk highest given policy divergence and geopolitical tension

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs; nitinol and bovine pericardium sourcing diversified, but specialized catheter component suppliers carry moderate substitutability risk

Medical device manufacturer; cloud disruption would impact back-office and analytics but not product delivery; core operations would continue with 30-day migration feasibility

Secondary SaaS-adjacent hemodynamic monitoring data platform (HemoSphere); cloud termination would disrupt data analytics offering but represents <10% of revenue

Low API coupling risk; EW uses standard hospital EMR integrations (HL7/FHIR); proprietary device ecosystems create hardware lock-in, not API dependency

Negligible Howey Test risk; revenue derived from FDA-regulated medical device sales and services, not investment contracts or token-based instruments

Very High

Moderate GDPR exposure via EU hemodynamic patient data in HemoSphere platform; CCPA applies to California-based clinical data; active compliance programs in place, no material fines recorded

Moderate; ~80% U.S. TAVR market share with Medtronic and Abbott as primary competitors; DOJ/FTC scrutiny possible on structural heart acquisitions; EU competition reviews ongoing

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~70% transactional (capital device sales); ~30% recurring via disposables/consumables per-procedure pull-through; no pure subscription model but consumables create annuity-like repeat revenue

Per-procedure disposable pull-through (transcatheter heart valves, hemodynamic monitors); high-margin recurring consumables tied to installed capital equipment base

Premium pricing supported by clinical outcomes data and FDA approval moats; hospital value analysis committees create downward pressure; GPO contracts limit pure price escalation above mid-single digits

Strong; 7-8/10; clinical differentiation and reimbursement coding (CPT) support pricing; limited generic competition in TAVR; gross margins ~76% validate pricing durability

78.0% Gross Margin (Premium (>60%))

Minimal free-rider risk; products require clinical training, hospital credentialing, and physician certification; high switching friction eliminates meaningful churn or free-riding behavior

Sublinear growth model; manufacturing automation and platform scalability allow ~15-20% revenue growth with ~8-10% headcount growth; R&D and sales force remain key variable costs

Low marginal cost for incremental disposable revenue once capital equipment installed; new geography expansion requires sales headcount investment; overall operating leverage positive at scale

Not applicable; EW does not operate a franchise network; hospital distribution handled via direct sales force and select distributors under strict regulatory compliance frameworks

At 10x scale, CAC efficiency improves as hospital network penetration deepens; key constraint is physician training capacity and OR slot availability, not marketing spend

Weak direct network effects; stronger data network effect via HemoSphere outcomes database improving algorithm accuracy; clinical evidence flywheel creates indirect competitive moat

9.3% Return on Assets (Excellent)

Tier 1 recession resistant; structural heart disease and critical care monitoring are non-deferrable procedures; 2020 COVID dip was procedural volume not demand destruction; rapid recovery confirmed

Hospitals and cardiac surgery centers (acute care); top 10 U.S. health systems represent estimated 20-25% of domestic TAVR volume; concentration moderate but manageable

Interventional cardiologists and cardiac surgeons as clinical champions; physician adoption drives hospital purchasing decisions; key opinion leader concentration creates influence dependency risk

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

4.3% CapEx / Revenue (Low-CapEx Asset-Light)

0001099800

EW